Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07

    • Beta-Amyloid (1-11) Research Applications, Clinical Value, a

    2025-09-08

    Beta-Amyloid (1-11): Research Applications, Clinical Value, and Future Directions in Neurodegenerative Disease Studies

    Introduction
    Beta-Amyloid (1-11) is a synthetic peptide corresponding to the N-terminal fragment of the amyloid-beta (Aβ) protein, comprising amino acids 1 through 11 of the full-length Aβ sequence. This fragment is of particular interest in neurodegenerative research, especially in the context of Alzheimer’s disease (AD), where amyloid-beta aggregation and deposition are central pathological features (Selkoe & Hardy, 2016, Neuron). The Aβ peptide is generated through sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases, resulting in peptides of varying lengths, most notably Aβ1-40 and Aβ1-42. The shorter Aβ1-11 fragment, while not a major component of amyloid plaques, has emerged as a valuable research tool for dissecting the early events of Aβ aggregation, antibody specificity, and the development of diagnostic and therapeutic strategies.

    Mechanistically, Beta-Amyloid (1-11) is utilized to study the initial steps of Aβ misfolding, oligomerization, and its interactions with cellular receptors and antibodies. Its defined sequence allows for precise epitope mapping and the generation of monoclonal antibodies targeting the N-terminal region of Aβ, which is critical for both immunodiagnostic and immunotherapeutic approaches (Sevigny et al., 2016, Nature). Additionally, Beta-Amyloid (1-11) serves as a substrate in enzymatic assays and as a control peptide in studies evaluating the specificity of anti-Aβ agents.

    Clinical Value and Applications
    The clinical value of Beta-Amyloid (1-11) lies primarily in its utility as a research reagent rather than a direct therapeutic agent. Its applications span several domains:

    1. **Antibody Development and Validation:** The N-terminal region of Aβ is a major target for therapeutic antibodies. Beta-Amyloid (1-11) is used to generate and validate monoclonal antibodies that recognize this epitope, which are crucial for both passive immunotherapy and diagnostic assays (Wang et al., 2018, J. Biol. Chem.).
    2. **Diagnostic Assays:** Beta-Amyloid (1-11) is incorporated into ELISA and other immunoassays to detect Aβ-specific antibodies or to quantify Aβ levels in biological samples, aiding in early diagnosis and monitoring of Alzheimer’s disease progression (Blennow & Zetterberg, 2018, Nat. Rev. Neurol.).
    3. **Aggregation Studies:** The peptide is used to model the initial stages of Aβ aggregation, providing insights into the molecular mechanisms underlying amyloidogenesis and facilitating the screening of aggregation inhibitors (Haass & Selkoe, 2007, Nat. Rev. Mol. Cell Biol.).
    4. **Epitope Mapping:** Beta-Amyloid (1-11) enables detailed mapping of antibody binding sites, which is essential for the rational design of next-generation immunotherapies and for understanding immune responses in AD patients (Sevigny et al., 2016, Nature).
    5. **Enzyme Substrate:** As a defined substrate, Beta-Amyloid (1-11) is used in studies of proteases such as neprilysin and insulin-degrading enzyme, which are involved in Aβ catabolism (Iwata et al., 2000, Science).

    [Related: actinomycine d] Key Challenges and Pain Points Addressed
    Current challenges in Alzheimer’s disease research and therapy include the need for highly specific diagnostic tools, effective immunotherapies, and a deeper understanding of the molecular events leading to Aβ aggregation and toxicity. Beta-Amyloid (1-11) addresses several of these pain points:

    - **Specificity in Antibody Development:** Full-length Aβ peptides can adopt multiple conformations and aggregate, complicating antibody generation. The use of Beta-Amyloid (1-11) allows for the production of antibodies with high specificity for the N-terminal epitope, reducing cross-reactivity and improving diagnostic accuracy (Wang et al., 2018, J. Biol. Chem.).
    - **Early Aggregation Studies:** Most research has focused on fibrillar Aβ, but early oligomeric species are now recognized as the primary neurotoxic agents. Beta-Amyloid (1-11) provides a model for studying these early events, which are difficult to capture with longer, aggregation-prone peptides (Haass & Selkoe, 2007, Nat. Rev. Mol. Cell Biol.).
    - **Standardization in Assays:** Variability in peptide length and aggregation state can confound assay results. The defined sequence and physicochemical properties of Beta-Amyloid (1-11) enhance reproducibility and standardization in both research and clinical settings (Blennow & Zetterberg, 2018, Nat. Rev. Neurol.).
    - **Facilitating Drug Discovery:** By enabling high-throughput screening of aggregation inhibitors and antibody candidates, Beta-Amyloid (1-11) accelerates the identification of promising therapeutic leads (Sevigny et al., 2016, Nature).

    Literature Review
    A growing body of literature supports the utility of Beta-Amyloid (1-11) in neurodegenerative disease research:

    1. **Sevigny et al. (2016, Nature):** This landmark study demonstrated the efficacy of aducanumab, a monoclonal antibody targeting aggregated Aβ, in reducing amyloid plaques in AD patients. The antibody’s specificity for the N-terminal region, mapped using peptides like Beta-Amyloid (1-11), was critical for its therapeutic effect.
    2. **Wang et al. (2018, J. Biol. Chem.):** The authors characterized a panel of monoclonal antibodies against Aβ, using Beta-Amyloid (1-11) for epitope mapping and specificity testing. Their findings highlighted the importance of N-terminal epitopes in antibody-mediated clearance of Aβ.
    3. **Blennow & Zetterberg (2018, Nat. Rev. Neurol.):** This review emphasized the role of Aβ peptides in CSF and plasma as biomarkers for AD. The use of short Aβ fragments, including Beta-Amyloid (1-11), in immunoassays was discussed as a means to improve diagnostic sensitivity and specificity.
    4. **Haass & Selkoe (2007, Nat. Rev. Mol. Cell Biol.):** The authors reviewed the molecular mechanisms of Aβ aggregation, noting that early oligomeric species, which can be modeled using short peptides like Beta-Amyloid (1-11), are central to AD pathogenesis.
    5. **Iwata et al. (2000, Science):** This study identified neprilysin as a key enzyme in Aβ degradation. Beta-Amyloid (1-11) was used as a substrate to measure enzymatic activity, providing insights into Aβ clearance mechanisms.
    6. **Selkoe & Hardy (2016, Neuron):** The review outlined the amyloid hypothesis of AD and discussed the value of synthetic Aβ fragments in elucidating the sequence of pathological events.
    7. **Walsh et al. (2002, Nature):** The authors demonstrated that soluble Aβ oligomers, rather than fibrils, impair synaptic function. Short Aβ peptides were instrumental in these studies, underscoring the importance of fragments like Beta-Amyloid (1-11) in modeling early toxic species.

    [Related: Biotin-tyramide] Experimental Data and Results
    Experimental studies employing Beta-Amyloid (1-11) have yielded several important findings:

    - **Antibody Epitope Mapping:** Using ELISA and surface plasmon resonance, researchers have shown that Beta-Amyloid (1-11) is recognized by a subset of anti-Aβ antibodies with high affinity, confirming its utility for antibody screening and validation (Wang et al., 2018, J. Biol. Chem.).
    - **Aggregation Kinetics:** In vitro assays reveal that Beta-Amyloid (1-11) does not readily form fibrils under physiological conditions, but can participate in early oligomerization events. This property makes it a useful model for studying the initial steps of Aβ misfolding (Haass & Selkoe, 2007, Nat. Rev. Mol. Cell Biol.).
    - **Enzymatic Degradation:** Beta-Amyloid (1-11) serves as a sensitive substrate for neprilysin and other Aβ-degrading enzymes. Kinetic analyses demonstrate rapid cleavage, supporting the hypothesis that N-terminal Aβ fragments are efficiently cleared in vivo (Iwata et al., 2000, Science).
    - **Immunoassay Development:** Incorporation of Beta-Amyloid (1-11) into sandwich ELISA formats enhances assay specificity for N-terminal Aβ, reducing background and improving detection limits in CSF and plasma samples (Blennow & Zetterberg, 2018, Nat. Rev. Neurol.).
    - **Toxicity Studies:** While full-length Aβ1 [Related: olaparib label] Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 21 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11580655